Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Qiagen (QGEN – Research Report), AmerisourceBergen (ABC – Research Report) and Doximity (DOCS – Research Report).
Qiagen (QGEN)
In a report released today, Derik De Bruin from Bank of America Securities maintained a Buy rating on Qiagen, with a price target of $55.00. The company’s shares closed last Tuesday at $45.83.
According to TipRanks.com, Bruin is a 4-star analyst with an average return of
Currently, the analyst consensus on Qiagen is a Strong Buy with an average price target of $55.55, implying a 21.1% upside from current levels. In a report issued on May 23, Morgan Stanley also upgraded the stock to Buy with a EUR50.00 price target.
See the top stocks recommended by analysts >>
AmerisourceBergen (ABC)
In a report released today, Michael Cherny from Bank of America Securities reiterated a Buy rating on AmerisourceBergen, with a price target of $200.00. The company’s shares closed last Tuesday at $174.37, close to its 52-week high of $176.62.
According to TipRanks.com, Cherny is a 4-star analyst with an average return of
Currently, the analyst consensus on AmerisourceBergen is a Strong Buy with an average price target of $191.50, a 9.4% upside from current levels. In a report issued on May 26, UBS also maintained a Buy rating on the stock with a $184.00 price target.
Doximity (DOCS)
In a report released today, Allen Lutz from Bank of America Securities maintained a Sell rating on Doximity, with a price target of $28.00. The company’s shares closed last Tuesday at $34.06.
According to TipRanks.com, Lutz is a 3-star analyst with an average return of
Doximity has an analyst consensus of Hold, with a price target consensus of $36.33.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on QGEN:
- Qiagen affirms 2023 adjusted EPS outlook at least $2.10, consensus $2.10
- Qiagen reports Q1 EPS 51c, consensus 47c
- QIAGEN welcomes U.S. Preventive Services Task Force reaffirmation for latent TB screening in populations at increased risk
- QIAGEN launches QIAstat-Dx in Japan with respiratory panel for syndromic testing
- QIAGEN announces expansion of Supervisory Board
